Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate for Osteoporosis in Spinal Cord Injury
NCT00138866Phase 3Completed
- Sponsor
- Toronto Rehabilitation Institute
- Start
- Nov 2004
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Risedronate with Placebo (2 arms). Primary endpoint: Change in bone mineral density of the distal femur at 18 months. Started Nov 2004; status: completed.
02
Drugs
risedronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00138866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138866.